People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas. This is the main result of a follow-up study conducted by Karolinska Institutet researchers amongst almost 300,000 male construction workers. The study is published today online in the prestigious medical journal The Lancet.
Tobacco smoking is a known risk factor for pancreatic cancer, which is an unusually malignant form of the disease. Since it is common for people who take snus a tobacco product designed for insertion between the gum and upper lip to also smoke cigarettes, the challenge facing epidemiological research into snus and cancer has been to isolate the effects of the different kinds of tobacco. What makes this new study unique is that it has been possible to study the correlation between snus and cancer risk in a large enough group of men who have never smoked.
The subjects attended health check ups between 1978 and 1992, during which they were asked to report on their smoking and snusing habits. The researchers have also studied rates of oral and lung cancer amongst the men, but found no correlation to snus.
"Were actually not that surprised," says project leader Professor Olof Nyrn of the Department of Medical Epidemiology and Biostatistics. "Pancreatic cancer has been under discussion in several earlier epidemiological studies on humans, both regarding Scandinavian snus and American smoke-free tobacco. On the other hand, previous studies of oral and lung cancer in relation to Scandinavian snus have been negative."
The main contribution of the new study is its conclusion that Swedish moist snus can be carcinogenic. However, the study also shows that the risks for users are small, and, as far as can be judged, much smaller than the risks associated with smoking.
"If 10,000 non-smoking snus users are monitored for ten years, according to our data, eight or nine of them will develop pancreatic can
'"/>
Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
10-May-2007